This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the ATTRibute Part B results on Acoramidis for patients with ATTR cardiomyopathy.

Ticker(s): BBIO, PFE, ALNY

Who's the expert?

Institution: Stanford

  • Cardiologist and physician Scientist at Amyloid Center at major academic center with a focus on Advanced Heart Failure and Transplant Cardiology.
  • Currently manages 200 patients with ATTR amyloidosis and has published numerous papers on this topic.
  • Research focuses on amyloidosis, transplant immunology, mechanical circulatory support, and non-ischemic cardiomyopathies.

Interview Questions

Please describe your background and patient setting

Added By: ben_admin

How many patients with cardiomyopathy do you manage? What % have ATTR cardiomyopathy?

Added By: ben_admin

What is your current treatment algorithm for ATTR CM patients?

Added By: ben_admin

What are your overall thoughts on the results from the Attribute-CM Phase B study?

Added By: ben_admin

Where would you see acoramidis fitting into your management of patients if approved?

Added By: ben_admin

Although we have limited data at this time, do you see any weaknesses of acoramidis vs tafamdis or any of the upcoming silencers?

Added By: user718eef9c

Do you see acoramidis as differentiated & superior to tafamidis or  not?  Recognizing the difficculties of cross-trial comparisons (which are particulalry acute here given how different placebo compared), do you think the performance that BBIO showed on mortality & CV hospitalizations is meaningfully superior to tafamidis?  What about the performance on biomarkets and also the data they provided on acoramidis vs. tafamidis based on the tafamidis drop-ins in the trial?    

Added By: jajay

What do you think about the safety / side-effect profile of acoramidis and how does that compare to tafamidis?  Any advantage or disadvantage there?

Added By: jajay

Some have metnioned that acoramidis and tafamidis will be huge beneficiaries of the Inflation Reduction Act.  There is a provision in there that takes the donut hole from $14K down to $2K.  Some have suggested this could double the market opportunity for this drug class as it becomes affordable for a lot more people.  What do you think about this notion?

Added By: jajay

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.